Posted by Michael Wonder on 12 Feb 2025
Health Canada approves Merck's Keytruda (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
11 February 2025 - Approval is based on the Phase 3 KEYNOTE-671 trial.
Merck announced that Health Canada has granted approval for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma in combination with platinum-containing chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
